Filing Flows › Fate Therapeutics (FATE) › Q1 2026
Fate Therapeutics (FATE) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Fate Therapeutics (FATE) reported revenue of $1.3M for the first quarter 2026 (Q1 2026), -20% from a year earlier and -5% from the quarter before.
Fate Therapeutics, Q1 2026: revenue $1.3M (-20% year over year), net loss $31.2M, operating cash flow −$30.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -5% | -20% |
| Operating profit | −$33.0M | — | — |
| Net earnings | −$31.2M | — | — |
| Operating cash flow | −$30.8M | — | — |
What changed
Revenue was $1.3M in Q1 2026, down 20% year over year and down 5% from the previous quarter.
Operating costs exceeded revenue by $33.0M, an operating margin of -2540.4%. Total costs fell 20% while revenue fell 20%. The quarter ended with a net loss of $31.2M, narrower than the previous quarter's $32.4M loss.
Operating cash flow was −$30.8M. Non-cash charges added back $2.9M of depreciation and amortization and $3.9M of share-based compensation. Working capital and other items used $6.5M. Capital expenditures of $239K exceeded it, leaving free cash flow of −$31.1M.
Questions
What was Fate Therapeutics' revenue in the first quarter 2026?
Fate Therapeutics (FATE) reported revenue of $1.3M for the first quarter 2026 (Q1 2026), -20% from a year earlier and -5% from the quarter before.
Source: Fate Therapeutics 10-Q on SEC EDGAR.